Periadventitial local drug delivery to target restenosis

Tesfamariam, Belay

doi:10.1016/j.vph.2017.12.062

Cited by 11 publications

(7 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Others also prove that TGFB1 plays an important role in modulating repair of vascular injury, including restenosis, after balloon angioplasty (31). TGFB1 can trigger the differentiation of the adventitia progenitors (32,33). In vivo, the overall effect of TGFB1 appears to be stimulation of neointimal hyperplasia (34,35).…”

Section: Discussionmentioning

confidence: 99%

PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease

Song¹,

Qing²,

Guo³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease

Song¹,

Qing²,

Guo³

et al. 2020

JCI Insight

View full text Add to dashboard Cite

“…Adventitia is a complex outermost layer of the vessel wall and a major site of immune surveillance and inflammatory cell trafficking, and actively participates in the initiation of vascular inflammation and neointimal formation following vascular injury [32] . Adventitia also have been shown to contain resident vascular progenitor cells express Sca-1 [33] .…”

Section: Discussionmentioning

confidence: 99%

Bone marrow-derived mesenchymal stem cells inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia after arterial injury in rats

Iso

Usui

Toyoda

et al. 2018

Biochemistry and Biophysics Reports

View full text Add to dashboard Cite

We investigated whether mesenchymal stem cell (MSC)-based treatment could inhibit neointimal hyperplasia in a rat model of carotid arterial injury and explored potential mechanisms underlying the positive effects of MSC therapy on vascular remodeling/repair. Sprague-Dawley rats underwent balloon injury to their right carotid arteries. After 2 days, we administered cultured MSCs from bone marrow of GFP-transgenic rats (0.8 × 106 cells, n = 10) or vehicle (controls, n = 10) to adventitial sites of the injured arteries. As an additional control, some rats received a higher dose of MSCs by systemic infusion (3 × 106 cells, tail vein; n = 4). Local vascular MSC administration significantly prevented neointimal hyperplasia (intima/media ratio) and reduced the percentage of Ki67 + proliferating cells in arterial walls by 14 days after treatment, despite little evidence of long-term MSC engraftment. Notably, systemic MSC infusion did not alter neointimal formation. By immunohistochemistry, compared with neointimal cells of controls, cells in MSC-treated arteries expressed reduced levels of embryonic myosin heavy chain and RM-4, an inflammatory cell marker. In the presence of platelet-derived growth factor (PDGF-BB), conditioned medium from MSCs increased p27 protein levels and significantly attenuated VSMC proliferation in culture. Furthermore, MSC-conditioned medium suppressed the expression of inflammatory cytokines and RM-4 in PDGF-BB-treated VSMCs. Thus, perivascular administration of MSCs may improve restenosis after vascular injury through paracrine effects that modulate VSMC inflammatory phenotype.

show abstract

“…Lipophilic drugs would elute slower than a hydrophilic drug; thus forming a drugdepot from where the drug would slowly dissipate. Therefore, lower amounts of drug and shorter duration of drug delivery is required to achieve optimum local drug levels [17].…”

Section: Micro Needle Injection Into Adventitiamentioning

confidence: 99%

Recent Advances in the Local Drug Delivery for the Treatment of Restenosis

Khatri

2018

MADD

View full text Add to dashboard Cite

Stent procedure and balloon angioplasty are two major approaches used in the treatment of Cardio vascular diseases. There have been significant advances in the treatment of these disorders and complication resulting from these treatment options i.e. Restenosis. This article focuses on the evolution and the recent advances in the different treatment options available for the preventing Restenosis after vascular intervention. The focal point of this review is the approaches for a localized drug delivery in the vascular walls.

show abstract

Periadventitial local drug delivery to target restenosis

Cited by 11 publications

References 46 publications

PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease

PDGFRA in vascular adventitial MSCs promotes neointima formation in arteriovenous fistula in chronic kidney disease

Bone marrow-derived mesenchymal stem cells inhibit vascular smooth muscle cell proliferation and neointimal hyperplasia after arterial injury in rats

Recent Advances in the Local Drug Delivery for the Treatment of Restenosis

Contact Info

Product

Resources

About